Bullish
Eli Lilly's Zepbound shows superior weight loss over Wegovy in new study.
Eli Lilly's Zepbound (tirzepatide) demonstrated greater weight loss compared to Novo Nordisk's Wegovy (semaglutide) in a recent indirect treatment comparison. The study found that Zepbound 15 mg led to an average body weight reduction 4.5% greater than Wegovy HD 7.2 mg over 72 weeks. Additionally, Zepbound 15 mg increased the odds of losing at least 20% of body weight by 3.54 times compared to Wegovy HD.
Key points
- Zepbound 15 mg outperforms Wegovy in weight loss efficacy.
- Study results are based on indirect comparisons; further direct trials are needed.
- Both treatments have similar safety profiles; adverse event discontinuation rates were comparable.
Sources
- Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparisonStockTitan · September 29, 2026
- Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparisonStockTitan · September 29, 2026
- Eli Lilly and Company (NYSE:LLY) Trading Down 1.2% - Time to Sell?MarketBeat · August 31, 2026
- Eli Lilly and Company (NYSE:LLY) Stock Price, News & AnalysisMarketBeat
AI-generated from public news sources. Not financial advice.
